Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda to Use Amgen Japanas Development Subsidiary
February 18, 2008
- No Problems Found in EPPV of Velcade, Alimta
February 18, 2008
- Repeat Consultation Fee for Clinics Will Not Be Cut: Chuikyo
February 11, 2008
- Actemra to Be Approved for RA
February 11, 2008
- REGULATORY NEWS IN BRIEF
February 11, 2008
- Japan Should Take Part in More Multinational Clinical Trials: JMACCT Conference
February 11, 2008
- Live Vaccine Development Important for New-type Influenza
February 11, 2008
- R&D NEWS IN BRIEF
February 11, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 11, 2008
- TOPICS／Merck Seiyaku Renamed Mylan Seiyaku
February 11, 2008
- Chugai's Sunrise 2012 Plan Calls For Sales of \460 Bil.
February 11, 2008
- Takeda Acquires Amgen in Japan
February 11, 2008
- NEW PRODUCTS／Bayer Launches EOB Primovist for MRI of the Liver
February 11, 2008
- Mediceo Paltac to Embark on Generics Business in Earnest
February 11, 2008
- BUSINESS NEWS IN BRIEF
February 11, 2008
- Shigeo Oyagi Elected President, CEO of Teijin Limited
February 11, 2008
- All ARBs, SSRIs to Be Re-priced
February 11, 2008
- Council Moving to Build Up Regional Clinical Trial Systems
February 4, 2008
- NEW PRODUCTS
February 4, 2008
- Public Opinions Invited on Draft Guidance on MD Studies
February 4, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…